Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Heart-Assist Devices | 62 | 2022 | 731 | 6.050 |
Why?
|
Heart Failure | 67 | 2023 | 1204 | 5.390 |
Why?
|
Ventricular Function, Left | 22 | 2023 | 592 | 2.190 |
Why?
|
Hemodynamics | 24 | 2022 | 710 | 2.140 |
Why?
|
Heart Ventricles | 19 | 2021 | 760 | 2.020 |
Why?
|
MicroRNAs | 7 | 2017 | 534 | 1.880 |
Why?
|
Heart Transplantation | 12 | 2021 | 705 | 1.450 |
Why?
|
Arrhythmias, Cardiac | 5 | 2017 | 187 | 1.420 |
Why?
|
Pulmonary Wedge Pressure | 12 | 2021 | 108 | 1.260 |
Why?
|
Middle Aged | 92 | 2023 | 25028 | 1.180 |
Why?
|
Myocardium | 6 | 2017 | 529 | 1.070 |
Why?
|
Cardiac Catheterization | 12 | 2020 | 291 | 1.050 |
Why?
|
Aortic Valve Insufficiency | 7 | 2020 | 130 | 1.050 |
Why?
|
Humans | 146 | 2023 | 86643 | 1.040 |
Why?
|
Male | 107 | 2023 | 40965 | 1.030 |
Why?
|
Female | 102 | 2023 | 44532 | 1.010 |
Why?
|
Prosthesis Implantation | 7 | 2020 | 125 | 0.980 |
Why?
|
Cardiomyopathies | 6 | 2020 | 240 | 0.980 |
Why?
|
Skin Neoplasms | 6 | 2020 | 546 | 0.940 |
Why?
|
Cornea | 2 | 2014 | 69 | 0.930 |
Why?
|
Ventricular Remodeling | 3 | 2021 | 96 | 0.880 |
Why?
|
Epigenesis, Genetic | 3 | 2017 | 479 | 0.850 |
Why?
|
Myocytes, Cardiac | 6 | 2016 | 275 | 0.840 |
Why?
|
Skin | 6 | 2020 | 554 | 0.810 |
Why?
|
Echocardiography | 16 | 2020 | 911 | 0.810 |
Why?
|
S100 Proteins | 5 | 2013 | 50 | 0.790 |
Why?
|
Gene Expression Regulation | 9 | 2017 | 1920 | 0.780 |
Why?
|
Folliculitis | 1 | 2020 | 2 | 0.740 |
Why?
|
Mesotherapy | 1 | 2020 | 2 | 0.740 |
Why?
|
Foot Diseases | 1 | 2019 | 12 | 0.730 |
Why?
|
Echocardiography, Doppler | 8 | 2020 | 187 | 0.730 |
Why?
|
Aged | 57 | 2023 | 18415 | 0.720 |
Why?
|
Foot | 1 | 2019 | 50 | 0.720 |
Why?
|
Hemangioma | 1 | 2019 | 60 | 0.710 |
Why?
|
Signal Transduction | 9 | 2020 | 3241 | 0.710 |
Why?
|
Gap Junctions | 2 | 2017 | 142 | 0.690 |
Why?
|
Immunoglobulin G | 4 | 2021 | 456 | 0.650 |
Why?
|
Treatment Outcome | 35 | 2023 | 7993 | 0.650 |
Why?
|
Melanoma | 4 | 2020 | 459 | 0.650 |
Why?
|
Cannula | 6 | 2020 | 47 | 0.640 |
Why?
|
Disease Models, Animal | 9 | 2019 | 2232 | 0.640 |
Why?
|
Cosmetic Techniques | 2 | 2015 | 28 | 0.640 |
Why?
|
Cardiology | 1 | 2019 | 123 | 0.620 |
Why?
|
Retrospective Studies | 34 | 2022 | 8489 | 0.620 |
Why?
|
Biopsy | 5 | 2019 | 1163 | 0.610 |
Why?
|
Desmosomes | 1 | 2017 | 10 | 0.610 |
Why?
|
Arrhythmogenic Right Ventricular Dysplasia | 1 | 2017 | 10 | 0.600 |
Why?
|
Adult | 45 | 2023 | 25648 | 0.590 |
Why?
|
Heart Atria | 2 | 2019 | 250 | 0.590 |
Why?
|
Prospective Studies | 26 | 2023 | 4213 | 0.580 |
Why?
|
Leg Dermatoses | 1 | 2016 | 7 | 0.580 |
Why?
|
Intra-Aortic Balloon Pumping | 4 | 2020 | 78 | 0.580 |
Why?
|
Cryptococcosis | 1 | 2016 | 11 | 0.580 |
Why?
|
Immunocompromised Host | 2 | 2020 | 140 | 0.570 |
Why?
|
Cellulitis | 1 | 2016 | 19 | 0.570 |
Why?
|
Regeneration | 1 | 2017 | 143 | 0.570 |
Why?
|
Fungemia | 1 | 2016 | 15 | 0.570 |
Why?
|
Cardiovascular Diseases | 2 | 2014 | 827 | 0.570 |
Why?
|
Glomerulosclerosis, Focal Segmental | 1 | 2016 | 38 | 0.560 |
Why?
|
Methanobrevibacter | 2 | 2013 | 2 | 0.550 |
Why?
|
Hemorrhage | 4 | 2018 | 268 | 0.550 |
Why?
|
Immunosuppressive Agents | 3 | 2020 | 977 | 0.530 |
Why?
|
Heart Conduction System | 2 | 2012 | 108 | 0.530 |
Why?
|
Cell Nucleus | 2 | 2017 | 579 | 0.530 |
Why?
|
Acupuncture Therapy | 1 | 2015 | 11 | 0.530 |
Why?
|
Medical Oncology | 1 | 2019 | 359 | 0.530 |
Why?
|
Sclerosis | 1 | 2015 | 28 | 0.520 |
Why?
|
Leg Ulcer | 1 | 2014 | 7 | 0.520 |
Why?
|
Animals | 38 | 2020 | 26582 | 0.510 |
Why?
|
Granuloma | 1 | 2015 | 65 | 0.510 |
Why?
|
Tetracaine | 1 | 2014 | 1 | 0.510 |
Why?
|
Eye Pain | 1 | 2014 | 4 | 0.510 |
Why?
|
Coated Materials, Biocompatible | 1 | 2014 | 30 | 0.510 |
Why?
|
Corneal Injuries | 1 | 2014 | 10 | 0.510 |
Why?
|
Thrombosis | 5 | 2020 | 296 | 0.510 |
Why?
|
Embolism | 1 | 2014 | 31 | 0.510 |
Why?
|
Irritable Bowel Syndrome | 2 | 2012 | 45 | 0.510 |
Why?
|
Eye Injuries | 1 | 2014 | 15 | 0.500 |
Why?
|
Membrane Glycoproteins | 1 | 2017 | 428 | 0.500 |
Why?
|
Cardiac Output | 6 | 2022 | 156 | 0.490 |
Why?
|
Keratomileusis, Laser In Situ | 1 | 2014 | 2 | 0.490 |
Why?
|
Face | 1 | 2015 | 114 | 0.490 |
Why?
|
Lasers, Excimer | 1 | 2014 | 5 | 0.490 |
Why?
|
Photorefractive Keratectomy | 1 | 2014 | 4 | 0.490 |
Why?
|
Myopia | 1 | 2014 | 10 | 0.490 |
Why?
|
Foreign Bodies | 1 | 2014 | 63 | 0.480 |
Why?
|
Ventricular Dysfunction, Right | 3 | 2020 | 134 | 0.480 |
Why?
|
Prednisone | 3 | 2020 | 258 | 0.480 |
Why?
|
Cardiomegaly | 6 | 2016 | 111 | 0.480 |
Why?
|
Anesthetics, Local | 1 | 2014 | 76 | 0.480 |
Why?
|
Trigeminal Nerve | 1 | 2013 | 18 | 0.480 |
Why?
|
Connexin 43 | 1 | 2014 | 94 | 0.470 |
Why?
|
Thromboembolism | 3 | 2018 | 119 | 0.460 |
Why?
|
Nerve Fibers | 1 | 2013 | 46 | 0.460 |
Why?
|
Device Removal | 3 | 2020 | 161 | 0.460 |
Why?
|
Panniculitis | 1 | 2013 | 8 | 0.460 |
Why?
|
Follow-Up Studies | 15 | 2021 | 3640 | 0.460 |
Why?
|
Fox-Fordyce Disease | 1 | 2012 | 2 | 0.450 |
Why?
|
Lactoglobulins | 1 | 2012 | 8 | 0.450 |
Why?
|
Xanthomatosis | 1 | 2012 | 5 | 0.450 |
Why?
|
Heart | 4 | 2019 | 539 | 0.450 |
Why?
|
Hypertrichosis | 1 | 2012 | 4 | 0.450 |
Why?
|
Neurocytoma | 1 | 2012 | 3 | 0.450 |
Why?
|
Facial Neoplasms | 1 | 2012 | 25 | 0.440 |
Why?
|
Methane | 1 | 2012 | 10 | 0.430 |
Why?
|
Mice | 24 | 2020 | 11352 | 0.420 |
Why?
|
Oxidation-Reduction | 1 | 2013 | 373 | 0.420 |
Why?
|
Mice, Transgenic | 13 | 2019 | 1540 | 0.410 |
Why?
|
Ultrasonography, Prenatal | 1 | 2013 | 152 | 0.410 |
Why?
|
Constipation | 1 | 2012 | 63 | 0.410 |
Why?
|
Histiocytosis, Non-Langerhans-Cell | 1 | 2011 | 3 | 0.410 |
Why?
|
Postoperative Complications | 9 | 2020 | 2207 | 0.410 |
Why?
|
Facial Dermatoses | 1 | 2011 | 13 | 0.400 |
Why?
|
Indoles | 1 | 2013 | 318 | 0.400 |
Why?
|
Sulfonamides | 1 | 2013 | 300 | 0.390 |
Why?
|
Diagnosis, Differential | 6 | 2019 | 1565 | 0.380 |
Why?
|
Hypertension, Pulmonary | 4 | 2020 | 346 | 0.380 |
Why?
|
Sirtuin 3 | 4 | 2016 | 29 | 0.380 |
Why?
|
Arterial Pressure | 3 | 2020 | 38 | 0.370 |
Why?
|
Histiocytosis, Sinus | 2 | 2020 | 14 | 0.360 |
Why?
|
Lymphedema | 3 | 2020 | 77 | 0.360 |
Why?
|
Atrial Fibrillation | 4 | 2019 | 288 | 0.360 |
Why?
|
Recovery of Function | 4 | 2019 | 272 | 0.360 |
Why?
|
CD18 Antigens | 1 | 2009 | 22 | 0.350 |
Why?
|
Aortic Valve | 4 | 2020 | 222 | 0.350 |
Why?
|
Echocardiography, Three-Dimensional | 4 | 2021 | 516 | 0.350 |
Why?
|
Methotrexate | 2 | 2020 | 249 | 0.340 |
Why?
|
Kidney Transplantation | 3 | 2021 | 849 | 0.340 |
Why?
|
Anti-Bacterial Agents | 3 | 2020 | 746 | 0.340 |
Why?
|
Tricuspid Valve | 2 | 2020 | 96 | 0.340 |
Why?
|
Heart Defects, Congenital | 3 | 2021 | 351 | 0.340 |
Why?
|
Liver Transplantation | 4 | 2021 | 1268 | 0.340 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2009 | 87 | 0.340 |
Why?
|
Pulmonary Artery | 3 | 2021 | 306 | 0.340 |
Why?
|
Autoimmune Diseases | 3 | 2021 | 241 | 0.330 |
Why?
|
Counterpulsation | 2 | 2018 | 21 | 0.320 |
Why?
|
Cardiotonic Agents | 3 | 2019 | 87 | 0.320 |
Why?
|
Tricuspid Valve Insufficiency | 2 | 2020 | 111 | 0.320 |
Why?
|
Pacemaker, Artificial | 2 | 2020 | 87 | 0.320 |
Why?
|
Heart Valve Prosthesis Implantation | 2 | 2020 | 166 | 0.320 |
Why?
|
Lymph Node Excision | 2 | 2019 | 217 | 0.310 |
Why?
|
Extracorporeal Membrane Oxygenation | 2 | 2020 | 139 | 0.310 |
Why?
|
Coronary Artery Bypass | 3 | 2020 | 228 | 0.310 |
Why?
|
Radiotherapy | 2 | 2019 | 328 | 0.310 |
Why?
|
Gastrointestinal Hemorrhage | 3 | 2020 | 229 | 0.310 |
Why?
|
Photosensitivity Disorders | 1 | 2007 | 15 | 0.300 |
Why?
|
Lichen Planus | 1 | 2007 | 10 | 0.300 |
Why?
|
Protein Biosynthesis | 1 | 2009 | 378 | 0.300 |
Why?
|
Ventricular Dysfunction, Left | 2 | 2023 | 318 | 0.300 |
Why?
|
Graft Rejection | 4 | 2021 | 1065 | 0.290 |
Why?
|
Muscle, Smooth, Vascular | 4 | 2013 | 231 | 0.290 |
Why?
|
Energy Metabolism | 2 | 2019 | 271 | 0.290 |
Why?
|
Wound Healing | 2 | 2020 | 344 | 0.280 |
Why?
|
Psoriasis | 1 | 2009 | 240 | 0.280 |
Why?
|
Leiomyomatosis | 1 | 2005 | 12 | 0.280 |
Why?
|
Transcription Factors | 2 | 2014 | 1565 | 0.270 |
Why?
|
Time Factors | 12 | 2021 | 5210 | 0.270 |
Why?
|
Ventricular Function, Right | 4 | 2020 | 142 | 0.270 |
Why?
|
Oxidative Stress | 4 | 2019 | 447 | 0.260 |
Why?
|
Nails, Malformed | 1 | 2004 | 3 | 0.260 |
Why?
|
Urticaria | 1 | 2004 | 10 | 0.260 |
Why?
|
Mitochondria | 3 | 2019 | 535 | 0.260 |
Why?
|
Craniofacial Abnormalities | 1 | 2004 | 36 | 0.250 |
Why?
|
Stroke Volume | 4 | 2023 | 456 | 0.250 |
Why?
|
Hair | 1 | 2004 | 56 | 0.250 |
Why?
|
Cold Temperature | 1 | 2004 | 157 | 0.250 |
Why?
|
DNA-Binding Proteins | 2 | 2012 | 1208 | 0.240 |
Why?
|
Aminobutyrates | 2 | 2023 | 13 | 0.240 |
Why?
|
Angiotensin Receptor Antagonists | 2 | 2023 | 80 | 0.240 |
Why?
|
Patient Readmission | 4 | 2020 | 329 | 0.230 |
Why?
|
Tetrazoles | 2 | 2023 | 50 | 0.230 |
Why?
|
Osteopoikilosis | 1 | 2003 | 1 | 0.230 |
Why?
|
Skin Diseases, Genetic | 1 | 2003 | 2 | 0.230 |
Why?
|
Sirtuins | 3 | 2016 | 45 | 0.230 |
Why?
|
Abnormalities, Multiple | 1 | 2004 | 232 | 0.230 |
Why?
|
Central Venous Pressure | 2 | 2020 | 26 | 0.230 |
Why?
|
Anticoagulants | 4 | 2019 | 408 | 0.230 |
Why?
|
T-Lymphocytes | 1 | 2009 | 1195 | 0.220 |
Why?
|
Survival Rate | 7 | 2021 | 1863 | 0.220 |
Why?
|
Transplant Recipients | 2 | 2021 | 122 | 0.210 |
Why?
|
Proportional Hazards Models | 6 | 2020 | 859 | 0.210 |
Why?
|
Complement C3d | 1 | 2021 | 6 | 0.210 |
Why?
|
3' Untranslated Regions | 2 | 2014 | 92 | 0.210 |
Why?
|
NIH 3T3 Cells | 2 | 2014 | 105 | 0.210 |
Why?
|
Uterine Neoplasms | 1 | 2005 | 227 | 0.210 |
Why?
|
Aortic Aneurysm | 2 | 2014 | 80 | 0.210 |
Why?
|
Skin Diseases, Vesiculobullous | 1 | 2021 | 18 | 0.210 |
Why?
|
Complement C4b | 1 | 2021 | 35 | 0.200 |
Why?
|
Blood Flow Velocity | 2 | 2019 | 197 | 0.200 |
Why?
|
Bone and Bones | 1 | 2003 | 265 | 0.200 |
Why?
|
Apolipoproteins E | 2 | 2013 | 129 | 0.200 |
Why?
|
Kidney Failure, Chronic | 2 | 2020 | 509 | 0.200 |
Why?
|
Risk Factors | 8 | 2020 | 5417 | 0.200 |
Why?
|
Cohort Studies | 9 | 2020 | 2767 | 0.200 |
Why?
|
Paraganglioma, Extra-Adrenal | 1 | 2020 | 12 | 0.190 |
Why?
|
Glomus Tumor | 1 | 2020 | 8 | 0.190 |
Why?
|
Penicillin G Benzathine | 1 | 2020 | 5 | 0.190 |
Why?
|
Agammaglobulinemia | 1 | 2020 | 20 | 0.190 |
Why?
|
Atherosclerosis | 2 | 2014 | 244 | 0.190 |
Why?
|
Sulfadiazine | 1 | 2020 | 24 | 0.190 |
Why?
|
Treponema pallidum | 1 | 2020 | 8 | 0.190 |
Why?
|
Trimethoprim | 1 | 2020 | 15 | 0.190 |
Why?
|
Risk Assessment | 5 | 2020 | 2261 | 0.190 |
Why?
|
Epidermolysis Bullosa, Junctional | 1 | 2020 | 1 | 0.190 |
Why?
|
Gentamicins | 1 | 2020 | 19 | 0.190 |
Why?
|
HIV Seropositivity | 1 | 2020 | 49 | 0.190 |
Why?
|
Ambulatory Care | 2 | 2018 | 181 | 0.190 |
Why?
|
Primary Graft Dysfunction | 1 | 2020 | 27 | 0.180 |
Why?
|
Cause of Death | 2 | 2018 | 277 | 0.180 |
Why?
|
Poroma | 1 | 2019 | 1 | 0.180 |
Why?
|
Codon, Nonsense | 1 | 2020 | 41 | 0.180 |
Why?
|
Antidiuretic Hormone Receptor Antagonists | 1 | 2020 | 29 | 0.180 |
Why?
|
Sweat Gland Neoplasms | 1 | 2019 | 6 | 0.180 |
Why?
|
Syphilis | 1 | 2020 | 27 | 0.180 |
Why?
|
Mathematical Concepts | 1 | 2020 | 18 | 0.180 |
Why?
|
Fontan Procedure | 1 | 2020 | 53 | 0.180 |
Why?
|
Porokeratosis | 1 | 2019 | 3 | 0.180 |
Why?
|
Ambulatory Surgical Procedures | 1 | 2020 | 74 | 0.180 |
Why?
|
Severity of Illness Index | 7 | 2020 | 1801 | 0.180 |
Why?
|
Cell-Free Nucleic Acids | 1 | 2021 | 71 | 0.180 |
Why?
|
Mice, Knockout | 8 | 2019 | 1924 | 0.180 |
Why?
|
Tachycardia, Ventricular | 1 | 2020 | 115 | 0.180 |
Why?
|
Vascular Stiffness | 1 | 2019 | 26 | 0.180 |
Why?
|
Intraoperative Care | 1 | 2020 | 82 | 0.180 |
Why?
|
Cartilage | 2 | 2018 | 113 | 0.180 |
Why?
|
Electric Impedance | 1 | 2020 | 104 | 0.180 |
Why?
|
Syndrome | 3 | 2005 | 446 | 0.180 |
Why?
|
Hair Follicle | 1 | 2019 | 26 | 0.180 |
Why?
|
Peptide Fragments | 1 | 2021 | 460 | 0.180 |
Why?
|
Protease Inhibitors | 1 | 2019 | 72 | 0.180 |
Why?
|
Cheek | 2 | 2011 | 22 | 0.180 |
Why?
|
Vasodilation | 1 | 2019 | 96 | 0.180 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2020 | 152 | 0.170 |
Why?
|
Cell Adhesion Molecules | 1 | 2020 | 163 | 0.170 |
Why?
|
Calcinosis | 2 | 2011 | 224 | 0.170 |
Why?
|
Neoplasms, Second Primary | 2 | 2020 | 252 | 0.170 |
Why?
|
Biphenyl Compounds | 2 | 2019 | 68 | 0.170 |
Why?
|
Myocarditis | 1 | 2019 | 50 | 0.170 |
Why?
|
Sternotomy | 1 | 2019 | 20 | 0.170 |
Why?
|
Remote Sensing Technology | 1 | 2018 | 5 | 0.170 |
Why?
|
Multiple Organ Failure | 1 | 2019 | 53 | 0.170 |
Why?
|
Assisted Circulation | 1 | 2018 | 15 | 0.170 |
Why?
|
Thyroid Diseases | 1 | 2019 | 104 | 0.170 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 1 | 2019 | 90 | 0.170 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 231 | 0.170 |
Why?
|
Heart Function Tests | 1 | 2018 | 30 | 0.170 |
Why?
|
Mice, Inbred C57BL | 9 | 2019 | 3092 | 0.170 |
Why?
|
Lunate Bone | 1 | 2018 | 2 | 0.170 |
Why?
|
Donor Selection | 1 | 2019 | 67 | 0.170 |
Why?
|
Guided Tissue Regeneration | 1 | 2018 | 7 | 0.170 |
Why?
|
Acellular Dermis | 1 | 2018 | 4 | 0.170 |
Why?
|
Trapezium Bone | 1 | 2018 | 7 | 0.170 |
Why?
|
Shock, Cardiogenic | 1 | 2019 | 95 | 0.170 |
Why?
|
Reperfusion Injury | 1 | 2020 | 131 | 0.170 |
Why?
|
Predictive Value of Tests | 6 | 2019 | 1673 | 0.170 |
Why?
|
Nerve Tissue Proteins | 2 | 2013 | 503 | 0.170 |
Why?
|
Atrial Appendage | 1 | 2018 | 26 | 0.160 |
Why?
|
Carpometacarpal Joints | 1 | 2018 | 13 | 0.160 |
Why?
|
Arthroplasty | 1 | 2018 | 27 | 0.160 |
Why?
|
Pemphigoid, Bullous | 2 | 2021 | 12 | 0.160 |
Why?
|
Alopecia | 2 | 2019 | 34 | 0.160 |
Why?
|
Subclavian Artery | 2 | 2015 | 44 | 0.160 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2018 | 56 | 0.160 |
Why?
|
Rats | 8 | 2020 | 3990 | 0.160 |
Why?
|
Enoxaparin | 1 | 2018 | 23 | 0.160 |
Why?
|
Catheter Ablation | 1 | 2020 | 233 | 0.160 |
Why?
|
Octreotide | 1 | 2018 | 16 | 0.160 |
Why?
|
Fatty Acids, Omega-3 | 1 | 2018 | 51 | 0.160 |
Why?
|
Mitral Valve | 1 | 2020 | 248 | 0.160 |
Why?
|
Testosterone | 1 | 2019 | 271 | 0.160 |
Why?
|
Equipment Failure | 4 | 2020 | 119 | 0.160 |
Why?
|
Tattooing | 1 | 2017 | 5 | 0.160 |
Why?
|
Erythema Nodosum | 1 | 2017 | 4 | 0.160 |
Why?
|
Cardiac Resynchronization Therapy | 1 | 2019 | 68 | 0.160 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2018 | 63 | 0.160 |
Why?
|
Graphite | 1 | 2017 | 12 | 0.160 |
Why?
|
Prostheses and Implants | 2 | 2018 | 121 | 0.160 |
Why?
|
Sarcoidosis, Pulmonary | 1 | 2017 | 17 | 0.160 |
Why?
|
Nevus, Pigmented | 1 | 2018 | 49 | 0.160 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2018 | 165 | 0.160 |
Why?
|
Eye Injuries, Penetrating | 1 | 2017 | 5 | 0.160 |
Why?
|
Skin Ulcer | 1 | 2017 | 25 | 0.160 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2018 | 100 | 0.150 |
Why?
|
Illusions | 1 | 2017 | 12 | 0.150 |
Why?
|
Thermodilution | 1 | 2017 | 21 | 0.150 |
Why?
|
Surgical Flaps | 1 | 2020 | 241 | 0.150 |
Why?
|
Heart Valve Diseases | 1 | 2018 | 109 | 0.150 |
Why?
|
Rhinoplasty | 1 | 2018 | 34 | 0.150 |
Why?
|
Secondary Prevention | 1 | 2018 | 162 | 0.150 |
Why?
|
Desmocollins | 1 | 2017 | 3 | 0.150 |
Why?
|
Prognosis | 6 | 2022 | 3679 | 0.150 |
Why?
|
Clinical Decision-Making | 1 | 2019 | 257 | 0.150 |
Why?
|
Atrial Remodeling | 1 | 2017 | 17 | 0.150 |
Why?
|
Atrial Flutter | 1 | 2017 | 33 | 0.150 |
Why?
|
Insulin Resistance | 1 | 2019 | 377 | 0.150 |
Why?
|
Gasotransmitters | 1 | 2017 | 14 | 0.150 |
Why?
|
Tachycardia, Atrioventricular Nodal Reentry | 1 | 2017 | 20 | 0.150 |
Why?
|
Betacoronavirus | 1 | 2020 | 258 | 0.150 |
Why?
|
Myocardial Ischemia | 2 | 2017 | 162 | 0.150 |
Why?
|
Fibronectins | 1 | 2017 | 93 | 0.150 |
Why?
|
Drug Combinations | 3 | 2023 | 224 | 0.140 |
Why?
|
Cryptococcus neoformans | 1 | 2016 | 9 | 0.140 |
Why?
|
Fluconazole | 1 | 2016 | 10 | 0.140 |
Why?
|
Flucytosine | 1 | 2016 | 11 | 0.140 |
Why?
|
Amphotericin B | 1 | 2016 | 34 | 0.140 |
Why?
|
Carbon Monoxide | 1 | 2017 | 90 | 0.140 |
Why?
|
Angiopoietin-2 | 1 | 2016 | 15 | 0.140 |
Why?
|
Visual Acuity | 2 | 2014 | 194 | 0.140 |
Why?
|
Hydrogen Sulfide | 1 | 2017 | 50 | 0.140 |
Why?
|
RNA, Long Noncoding | 1 | 2017 | 102 | 0.140 |
Why?
|
Prosthesis Design | 4 | 2019 | 278 | 0.140 |
Why?
|
Tumor Suppressor Proteins | 1 | 2018 | 279 | 0.140 |
Why?
|
Defibrillators, Implantable | 1 | 2018 | 129 | 0.140 |
Why?
|
Reproducibility of Results | 4 | 2018 | 2705 | 0.140 |
Why?
|
Radiation Injuries | 1 | 2017 | 155 | 0.140 |
Why?
|
Coloring Agents | 2 | 2012 | 64 | 0.140 |
Why?
|
Lymph Nodes | 1 | 2020 | 533 | 0.140 |
Why?
|
Extracellular Matrix | 1 | 2017 | 232 | 0.140 |
Why?
|
Mitochondria, Heart | 1 | 2016 | 50 | 0.140 |
Why?
|
Superoxide Dismutase | 3 | 2015 | 177 | 0.140 |
Why?
|
Sleep Apnea Syndromes | 1 | 2017 | 103 | 0.140 |
Why?
|
Observer Variation | 2 | 2016 | 602 | 0.130 |
Why?
|
Antifungal Agents | 1 | 2016 | 117 | 0.130 |
Why?
|
Rats, Inbred SHR | 2 | 2017 | 29 | 0.130 |
Why?
|
Cyclosporine | 1 | 2016 | 234 | 0.130 |
Why?
|
Phenotype | 3 | 2017 | 2378 | 0.130 |
Why?
|
Lignans | 1 | 2015 | 6 | 0.130 |
Why?
|
Incidence | 5 | 2019 | 1577 | 0.130 |
Why?
|
Tissue and Organ Procurement | 1 | 2019 | 311 | 0.130 |
Why?
|
DNA, Mitochondrial | 1 | 2016 | 183 | 0.130 |
Why?
|
Lasers, Gas | 1 | 2014 | 4 | 0.130 |
Why?
|
Doxorubicin | 1 | 2016 | 295 | 0.130 |
Why?
|
Sensitivity and Specificity | 4 | 2018 | 1991 | 0.130 |
Why?
|
Low-Level Light Therapy | 1 | 2014 | 15 | 0.130 |
Why?
|
Cellular Reprogramming Techniques | 1 | 2014 | 6 | 0.130 |
Why?
|
Combined Modality Therapy | 1 | 2019 | 1686 | 0.130 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 316 | 0.130 |
Why?
|
Cephalosporins | 1 | 2014 | 24 | 0.130 |
Why?
|
Coronavirus Infections | 1 | 2020 | 301 | 0.130 |
Why?
|
LIM Domain Proteins | 1 | 2014 | 25 | 0.130 |
Why?
|
Conjunctiva | 1 | 2014 | 19 | 0.130 |
Why?
|
Amnion | 1 | 2014 | 14 | 0.130 |
Why?
|
Stevens-Johnson Syndrome | 1 | 2014 | 22 | 0.130 |
Why?
|
Muscular Dystrophy, Emery-Dreifuss | 1 | 2014 | 14 | 0.130 |
Why?
|
Mesenteric Artery, Superior | 1 | 2014 | 19 | 0.130 |
Why?
|
Toxoplasmosis | 1 | 2015 | 64 | 0.130 |
Why?
|
Immunohistochemistry | 4 | 2021 | 1753 | 0.120 |
Why?
|
Mitral Valve Insufficiency | 1 | 2016 | 187 | 0.120 |
Why?
|
Emergency Service, Hospital | 1 | 2018 | 484 | 0.120 |
Why?
|
Infant | 3 | 2021 | 3046 | 0.120 |
Why?
|
Refraction, Ocular | 1 | 2014 | 9 | 0.120 |
Why?
|
Melkersson-Rosenthal Syndrome | 1 | 2014 | 1 | 0.120 |
Why?
|
Gastrointestinal Agents | 2 | 2018 | 161 | 0.120 |
Why?
|
Eyelid Diseases | 1 | 2014 | 6 | 0.120 |
Why?
|
Sulfonylurea Receptors | 1 | 2014 | 50 | 0.120 |
Why?
|
Posture | 1 | 2014 | 125 | 0.120 |
Why?
|
Fluorescent Antibody Technique, Direct | 1 | 2014 | 10 | 0.120 |
Why?
|
Transduction, Genetic | 1 | 2014 | 153 | 0.120 |
Why?
|
Nails | 1 | 2014 | 7 | 0.120 |
Why?
|
Cells, Cultured | 6 | 2020 | 2818 | 0.120 |
Why?
|
Mutation, Missense | 2 | 2013 | 276 | 0.120 |
Why?
|
Luciferases | 1 | 2014 | 118 | 0.120 |
Why?
|
Catheterization, Peripheral | 1 | 2014 | 58 | 0.120 |
Why?
|
Connective Tissue Diseases | 1 | 2014 | 67 | 0.120 |
Why?
|
Electrocardiography | 4 | 2019 | 478 | 0.120 |
Why?
|
Myosin Heavy Chains | 1 | 2014 | 88 | 0.120 |
Why?
|
Genetic Testing | 1 | 2018 | 535 | 0.120 |
Why?
|
Patient Positioning | 1 | 2014 | 63 | 0.120 |
Why?
|
Neovascularization, Pathologic | 1 | 2016 | 353 | 0.120 |
Why?
|
Transforming Growth Factor beta | 2 | 2013 | 301 | 0.120 |
Why?
|
DNA Damage | 1 | 2016 | 366 | 0.120 |
Why?
|
Exosomes | 1 | 2014 | 50 | 0.120 |
Why?
|
Hospitalization | 1 | 2019 | 849 | 0.120 |
Why?
|
Neoplasm Metastasis | 2 | 2020 | 1056 | 0.120 |
Why?
|
Edema | 1 | 2014 | 71 | 0.120 |
Why?
|
Arterial Occlusive Diseases | 1 | 2014 | 107 | 0.120 |
Why?
|
Frozen Sections | 1 | 2014 | 48 | 0.120 |
Why?
|
Suture Techniques | 1 | 2014 | 135 | 0.120 |
Why?
|
Vasculitis | 2 | 2013 | 39 | 0.120 |
Why?
|
Genes, Reporter | 1 | 2014 | 268 | 0.120 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2020 | 1076 | 0.120 |
Why?
|
Oxygen Consumption | 1 | 2014 | 239 | 0.110 |
Why?
|
Tomography, X-Ray Computed | 3 | 2017 | 2601 | 0.110 |
Why?
|
Carmine | 1 | 2012 | 1 | 0.110 |
Why?
|
Illinois | 3 | 2019 | 462 | 0.110 |
Why?
|
Foam Cells | 1 | 2012 | 17 | 0.110 |
Why?
|
Nicotinamide Phosphoribosyltransferase | 1 | 2012 | 8 | 0.110 |
Why?
|
Genetic Vectors | 1 | 2014 | 439 | 0.110 |
Why?
|
Healthy Volunteers | 1 | 2013 | 143 | 0.110 |
Why?
|
Reoperation | 3 | 2020 | 597 | 0.110 |
Why?
|
Oncogene Protein v-akt | 1 | 2012 | 21 | 0.110 |
Why?
|
Mucins | 1 | 2012 | 39 | 0.110 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 2012 | 44 | 0.110 |
Why?
|
Microscopy, Confocal | 1 | 2013 | 268 | 0.110 |
Why?
|
Electrophysiological Phenomena | 1 | 2012 | 49 | 0.110 |
Why?
|
Models, Cardiovascular | 1 | 2012 | 98 | 0.110 |
Why?
|
Plaque, Atherosclerotic | 1 | 2013 | 54 | 0.110 |
Why?
|
Axilla | 1 | 2012 | 99 | 0.110 |
Why?
|
Lung | 1 | 2018 | 1170 | 0.110 |
Why?
|
Breath Tests | 1 | 2012 | 55 | 0.110 |
Why?
|
Staining and Labeling | 1 | 2012 | 165 | 0.110 |
Why?
|
Quinolines | 1 | 2013 | 95 | 0.110 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 1 | 2012 | 113 | 0.110 |
Why?
|
RNA, Small Interfering | 1 | 2014 | 547 | 0.110 |
Why?
|
Rats, Sprague-Dawley | 4 | 2020 | 1219 | 0.110 |
Why?
|
Weight Gain | 1 | 2013 | 123 | 0.110 |
Why?
|
Recombinant Fusion Proteins | 1 | 2014 | 557 | 0.110 |
Why?
|
Hydrogen | 1 | 2012 | 47 | 0.110 |
Why?
|
Calcium Signaling | 1 | 2012 | 129 | 0.110 |
Why?
|
Valsartan | 2 | 2023 | 20 | 0.110 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2013 | 138 | 0.100 |
Why?
|
Collagen Type VII | 1 | 2011 | 3 | 0.100 |
Why?
|
Epidermolysis Bullosa Acquisita | 1 | 2011 | 2 | 0.100 |
Why?
|
Feasibility Studies | 3 | 2018 | 751 | 0.100 |
Why?
|
Amino Acid Substitution | 1 | 2013 | 339 | 0.100 |
Why?
|
Cell Communication | 1 | 2012 | 194 | 0.100 |
Why?
|
Biomarkers | 3 | 2018 | 1718 | 0.100 |
Why?
|
Dermatologic Agents | 1 | 2012 | 71 | 0.100 |
Why?
|
Diabetes Mellitus | 1 | 2019 | 806 | 0.100 |
Why?
|
RNA, Bacterial | 1 | 2012 | 108 | 0.100 |
Why?
|
Physicians | 1 | 2019 | 673 | 0.100 |
Why?
|
Coronary Artery Disease | 1 | 2016 | 350 | 0.100 |
Why?
|
Rifamycins | 1 | 2011 | 5 | 0.100 |
Why?
|
S100A12 Protein | 4 | 2013 | 10 | 0.100 |
Why?
|
Sodium Channels | 1 | 2012 | 129 | 0.100 |
Why?
|
Muscle, Skeletal | 1 | 2014 | 449 | 0.100 |
Why?
|
Homeostasis | 1 | 2013 | 409 | 0.100 |
Why?
|
DNA, Bacterial | 1 | 2012 | 236 | 0.100 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2012 | 241 | 0.100 |
Why?
|
Environment | 1 | 2013 | 219 | 0.100 |
Why?
|
Disease Progression | 3 | 2020 | 1531 | 0.100 |
Why?
|
Kaplan-Meier Estimate | 3 | 2018 | 860 | 0.100 |
Why?
|
Ion Channels | 1 | 2012 | 246 | 0.100 |
Why?
|
T-Box Domain Proteins | 1 | 2012 | 118 | 0.100 |
Why?
|
Intestine, Small | 1 | 2013 | 303 | 0.100 |
Why?
|
Histones | 1 | 2013 | 311 | 0.100 |
Why?
|
Muscle Contraction | 3 | 2019 | 283 | 0.100 |
Why?
|
Child, Preschool | 3 | 2020 | 3612 | 0.100 |
Why?
|
Fibroblasts | 4 | 2016 | 729 | 0.090 |
Why?
|
Recurrence | 3 | 2018 | 1139 | 0.090 |
Why?
|
Feces | 1 | 2012 | 319 | 0.090 |
Why?
|
Mitochondria, Muscle | 1 | 2010 | 26 | 0.090 |
Why?
|
Proto-Oncogene Protein c-ets-1 | 1 | 2010 | 14 | 0.090 |
Why?
|
Ergocalciferols | 1 | 2010 | 38 | 0.090 |
Why?
|
Child | 3 | 2021 | 6927 | 0.090 |
Why?
|
Autoimmunity | 1 | 2011 | 160 | 0.090 |
Why?
|
Neural Crest | 1 | 2010 | 25 | 0.090 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 2010 | 73 | 0.090 |
Why?
|
Vascular Diseases | 1 | 2011 | 121 | 0.090 |
Why?
|
NAD | 1 | 2009 | 65 | 0.090 |
Why?
|
Rare Diseases | 2 | 2020 | 59 | 0.090 |
Why?
|
Allografts | 2 | 2021 | 172 | 0.090 |
Why?
|
Lymphatic System | 2 | 2019 | 53 | 0.090 |
Why?
|
AMP-Activated Protein Kinases | 1 | 2009 | 64 | 0.090 |
Why?
|
Aged, 80 and over | 4 | 2020 | 6509 | 0.090 |
Why?
|
Biopsy, Needle | 2 | 2020 | 235 | 0.090 |
Why?
|
Mice, Inbred Strains | 1 | 2009 | 307 | 0.080 |
Why?
|
Osteogenesis | 1 | 2010 | 242 | 0.080 |
Why?
|
Longitudinal Studies | 2 | 2023 | 1019 | 0.080 |
Why?
|
Cell Proliferation | 2 | 2015 | 1578 | 0.080 |
Why?
|
Delayed-Action Preparations | 2 | 2019 | 116 | 0.080 |
Why?
|
Mitochondrial Proteins | 1 | 2009 | 123 | 0.080 |
Why?
|
Forkhead Transcription Factors | 1 | 2009 | 166 | 0.080 |
Why?
|
DNA Methylation | 1 | 2013 | 628 | 0.080 |
Why?
|
Antineoplastic Agents | 1 | 2019 | 2360 | 0.080 |
Why?
|
Cell Differentiation | 2 | 2015 | 1458 | 0.080 |
Why?
|
Young Adult | 4 | 2021 | 5976 | 0.080 |
Why?
|
Vitamin D | 1 | 2010 | 261 | 0.080 |
Why?
|
Blood Pressure | 1 | 2013 | 1143 | 0.080 |
Why?
|
Tissue Donors | 2 | 2021 | 463 | 0.080 |
Why?
|
Hydroquinones | 1 | 2007 | 8 | 0.080 |
Why?
|
Forehead | 1 | 2007 | 15 | 0.070 |
Why?
|
Hair Removal | 1 | 2007 | 14 | 0.070 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2012 | 930 | 0.070 |
Why?
|
Exercise Test | 2 | 2019 | 164 | 0.070 |
Why?
|
Reactive Oxygen Species | 3 | 2016 | 480 | 0.070 |
Why?
|
Radiation-Protective Agents | 1 | 2007 | 96 | 0.070 |
Why?
|
United States | 4 | 2021 | 6672 | 0.070 |
Why?
|
Cell Movement | 1 | 2010 | 758 | 0.070 |
Why?
|
Reference Values | 2 | 2018 | 674 | 0.070 |
Why?
|
Fumarate Hydratase | 1 | 2005 | 6 | 0.070 |
Why?
|
Comorbidity | 2 | 2020 | 943 | 0.070 |
Why?
|
Ultraviolet Rays | 1 | 2007 | 193 | 0.070 |
Why?
|
Academic Medical Centers | 2 | 2018 | 379 | 0.070 |
Why?
|
Pregnancy | 1 | 2013 | 2894 | 0.070 |
Why?
|
Alopecia Areata | 1 | 2005 | 4 | 0.070 |
Why?
|
Survival Analysis | 2 | 2020 | 1538 | 0.070 |
Why?
|
Patient Selection | 2 | 2020 | 685 | 0.070 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2005 | 88 | 0.070 |
Why?
|
Hydrocortisone | 1 | 2007 | 298 | 0.060 |
Why?
|
Nuclear Proteins | 1 | 2009 | 696 | 0.060 |
Why?
|
Point Mutation | 1 | 2005 | 246 | 0.060 |
Why?
|
Acetylcholine | 1 | 2004 | 176 | 0.060 |
Why?
|
Ultrasonography | 2 | 2020 | 695 | 0.060 |
Why?
|
Random Allocation | 2 | 2018 | 332 | 0.060 |
Why?
|
Dacryocystorhinostomy | 1 | 2004 | 4 | 0.060 |
Why?
|
Anti-Inflammatory Agents | 1 | 2007 | 339 | 0.060 |
Why?
|
Treatment Failure | 2 | 2020 | 285 | 0.060 |
Why?
|
Acetylation | 2 | 2015 | 121 | 0.060 |
Why?
|
Collagen | 2 | 2019 | 269 | 0.060 |
Why?
|
Age Factors | 2 | 2018 | 1851 | 0.060 |
Why?
|
Mitogen-Activated Protein Kinases | 2 | 2014 | 222 | 0.060 |
Why?
|
Elastic Tissue | 2 | 2014 | 18 | 0.050 |
Why?
|
Animals, Newborn | 2 | 2014 | 510 | 0.050 |
Why?
|
Dermatitis Herpetiformis | 1 | 2021 | 9 | 0.050 |
Why?
|
RNA, Messenger | 3 | 2013 | 1981 | 0.050 |
Why?
|
Receptor for Advanced Glycation End Products | 2 | 2013 | 17 | 0.050 |
Why?
|
Pemphigus | 1 | 2021 | 14 | 0.050 |
Why?
|
Paraffin Embedding | 1 | 2021 | 78 | 0.050 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2005 | 683 | 0.050 |
Why?
|
Immunoglobulin A | 1 | 2021 | 80 | 0.050 |
Why?
|
Immunoglobulin M | 1 | 2021 | 154 | 0.050 |
Why?
|
ABO Blood-Group System | 1 | 2021 | 62 | 0.050 |
Why?
|
Myocytes, Smooth Muscle | 2 | 2013 | 132 | 0.050 |
Why?
|
Catheterization, Swan-Ganz | 1 | 2021 | 25 | 0.050 |
Why?
|
Bilirubin | 1 | 2021 | 125 | 0.050 |
Why?
|
Pilot Projects | 2 | 2019 | 839 | 0.050 |
Why?
|
Radiography | 1 | 2003 | 813 | 0.050 |
Why?
|
Axillary Artery | 1 | 2020 | 10 | 0.050 |
Why?
|
Trauma Severity Indices | 1 | 2020 | 41 | 0.050 |
Why?
|
Aorta | 2 | 2013 | 280 | 0.050 |
Why?
|
Receptors, Immunologic | 2 | 2013 | 135 | 0.050 |
Why?
|
Syphilis Serodiagnosis | 1 | 2020 | 5 | 0.050 |
Why?
|
Syphilis, Cutaneous | 1 | 2020 | 3 | 0.050 |
Why?
|
Immunocompetence | 1 | 2020 | 27 | 0.050 |
Why?
|
Mice, Inbred ICR | 1 | 2020 | 70 | 0.050 |
Why?
|
California | 1 | 2020 | 138 | 0.050 |
Why?
|
Thoracic Surgical Procedures | 1 | 2020 | 44 | 0.050 |
Why?
|
Administration, Cutaneous | 1 | 2020 | 58 | 0.050 |
Why?
|
Epigastric Arteries | 1 | 2020 | 9 | 0.050 |
Why?
|
Hyponatremia | 1 | 2020 | 25 | 0.050 |
Why?
|
Rats, Transgenic | 1 | 2019 | 6 | 0.050 |
Why?
|
Exanthema | 1 | 2020 | 36 | 0.050 |
Why?
|
Euthyroid Sick Syndromes | 1 | 2019 | 11 | 0.050 |
Why?
|
Dissection | 1 | 2020 | 42 | 0.050 |
Why?
|
Neurotransmitter Agents | 1 | 2020 | 106 | 0.050 |
Why?
|
Endocrine System Diseases | 1 | 2019 | 23 | 0.040 |
Why?
|
Reperfusion | 1 | 2020 | 31 | 0.040 |
Why?
|
Hemodynamic Monitoring | 1 | 2019 | 8 | 0.040 |
Why?
|
Succinate Dehydrogenase | 1 | 2019 | 17 | 0.040 |
Why?
|
Patient Care Planning | 1 | 2020 | 81 | 0.040 |
Why?
|
Neprilysin | 1 | 2019 | 42 | 0.040 |
Why?
|
Femoral Artery | 1 | 2020 | 81 | 0.040 |
Why?
|
Sturge-Weber Syndrome | 1 | 2019 | 8 | 0.040 |
Why?
|
Electron Transport Complex IV | 1 | 2019 | 47 | 0.040 |
Why?
|
Fatal Outcome | 1 | 2020 | 293 | 0.040 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2019 | 35 | 0.040 |
Why?
|
Diabetes Complications | 1 | 2021 | 207 | 0.040 |
Why?
|
Materials Testing | 1 | 2019 | 91 | 0.040 |
Why?
|
Hyperthyroidism | 1 | 2019 | 75 | 0.040 |
Why?
|
Interdisciplinary Communication | 1 | 2020 | 130 | 0.040 |
Why?
|
Metabolic Diseases | 1 | 2019 | 48 | 0.040 |
Why?
|
Keratinocytes | 1 | 2020 | 143 | 0.040 |
Why?
|
Hyperplasia | 1 | 2019 | 148 | 0.040 |
Why?
|
Neck | 1 | 2019 | 100 | 0.040 |
Why?
|
Hindlimb | 1 | 2019 | 89 | 0.040 |
Why?
|
Heparin | 1 | 2019 | 175 | 0.040 |
Why?
|
Epidermis | 1 | 2019 | 100 | 0.040 |
Why?
|
Head | 1 | 2019 | 132 | 0.040 |
Why?
|
Systole | 1 | 2019 | 129 | 0.040 |
Why?
|
Administration, Oral | 1 | 2020 | 684 | 0.040 |
Why?
|
Operative Time | 1 | 2019 | 127 | 0.040 |
Why?
|
Thyrotropin | 1 | 2019 | 280 | 0.040 |
Why?
|
Patient Compliance | 1 | 2020 | 227 | 0.040 |
Why?
|
Organ Size | 1 | 2019 | 364 | 0.040 |
Why?
|
Transplantation, Homologous | 1 | 2021 | 996 | 0.040 |
Why?
|
Green Fluorescent Proteins | 1 | 2019 | 305 | 0.040 |
Why?
|
Mutation | 1 | 2009 | 3968 | 0.040 |
Why?
|
Coronary Circulation | 1 | 2018 | 130 | 0.040 |
Why?
|
Injections, Intramuscular | 1 | 2018 | 62 | 0.040 |
Why?
|
Rats, Nude | 1 | 2018 | 22 | 0.040 |
Why?
|
Ink | 1 | 2017 | 4 | 0.040 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2019 | 151 | 0.040 |
Why?
|
International Normalized Ratio | 1 | 2018 | 38 | 0.040 |
Why?
|
Medical History Taking | 1 | 2018 | 80 | 0.040 |
Why?
|
Fascia | 1 | 2018 | 30 | 0.040 |
Why?
|
Thyroxine | 1 | 2019 | 344 | 0.040 |
Why?
|
Ischemia | 1 | 2020 | 243 | 0.040 |
Why?
|
Databases, Factual | 1 | 2021 | 814 | 0.040 |
Why?
|
Hospitals, University | 1 | 2018 | 194 | 0.040 |
Why?
|
Ophthalmologists | 1 | 2017 | 5 | 0.040 |
Why?
|
Hypothyroidism | 1 | 2019 | 232 | 0.040 |
Why?
|
Graft Survival | 1 | 2021 | 884 | 0.040 |
Why?
|
Registries | 1 | 2021 | 702 | 0.040 |
Why?
|
Neutropenia | 1 | 2018 | 215 | 0.040 |
Why?
|
Protein Binding | 2 | 2013 | 1456 | 0.040 |
Why?
|
Cell Survival | 1 | 2020 | 969 | 0.040 |
Why?
|
Administration, Topical | 1 | 2017 | 95 | 0.040 |
Why?
|
Drug Therapy, Combination | 1 | 2020 | 894 | 0.040 |
Why?
|
Protein Array Analysis | 1 | 2017 | 50 | 0.040 |
Why?
|
Rabbits | 1 | 2018 | 636 | 0.040 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 199 | 0.040 |
Why?
|
Hypoalbuminemia | 1 | 2017 | 9 | 0.040 |
Why?
|
Rats, Inbred WKY | 1 | 2017 | 31 | 0.040 |
Why?
|
Radiologists | 1 | 2017 | 46 | 0.040 |
Why?
|
Tachycardia | 1 | 2017 | 35 | 0.040 |
Why?
|
Heme Oxygenase (Decyclizing) | 1 | 2017 | 44 | 0.040 |
Why?
|
Cystathionine gamma-Lyase | 1 | 2017 | 35 | 0.040 |
Why?
|
Epithelium | 1 | 2018 | 319 | 0.040 |
Why?
|
Hospital Mortality | 1 | 2019 | 349 | 0.040 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2018 | 134 | 0.040 |
Why?
|
Chi-Square Distribution | 1 | 2017 | 364 | 0.040 |
Why?
|
Transplantation, Autologous | 1 | 2018 | 331 | 0.040 |
Why?
|
Risk | 1 | 2018 | 674 | 0.040 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2001 | 384 | 0.040 |
Why?
|
Magnetic Resonance Imaging, Cine | 1 | 2018 | 159 | 0.040 |
Why?
|
Equipment Safety | 1 | 2016 | 31 | 0.040 |
Why?
|
Prevalence | 1 | 2020 | 1239 | 0.040 |
Why?
|
Swine | 1 | 2018 | 555 | 0.040 |
Why?
|
Thrombin | 1 | 2016 | 61 | 0.040 |
Why?
|
Human Umbilical Vein Endothelial Cells | 1 | 2016 | 63 | 0.040 |
Why?
|
DNA Adducts | 1 | 2016 | 21 | 0.040 |
Why?
|
Renal Insufficiency | 1 | 2017 | 114 | 0.030 |
Why?
|
Length of Stay | 1 | 2019 | 702 | 0.030 |
Why?
|
DNA Glycosylases | 1 | 2016 | 24 | 0.030 |
Why?
|
Deoxyguanosine | 1 | 2016 | 28 | 0.030 |
Why?
|
Adolescent | 2 | 2020 | 8981 | 0.030 |
Why?
|
Arteriovenous Malformations | 1 | 2016 | 41 | 0.030 |
Why?
|
Hydrolysis | 1 | 2016 | 141 | 0.030 |
Why?
|
Atovaquone | 1 | 2015 | 3 | 0.030 |
Why?
|
Prosthesis Failure | 1 | 2016 | 111 | 0.030 |
Why?
|
Contrast Media | 1 | 2020 | 1078 | 0.030 |
Why?
|
Mitochondrial Proton-Translocating ATPases | 1 | 2015 | 5 | 0.030 |
Why?
|
Germ-Line Mutation | 1 | 2018 | 329 | 0.030 |
Why?
|
Phenylephrine | 1 | 2015 | 35 | 0.030 |
Why?
|
Exercise Tolerance | 1 | 2015 | 48 | 0.030 |
Why?
|
Isoproterenol | 1 | 2015 | 59 | 0.030 |
Why?
|
Sex Factors | 1 | 2018 | 1054 | 0.030 |
Why?
|
Primary Cell Culture | 1 | 2015 | 72 | 0.030 |
Why?
|
Respiration | 1 | 2017 | 262 | 0.030 |
Why?
|
Neuromuscular Junction Diseases | 1 | 2014 | 3 | 0.030 |
Why?
|
Equipment Design | 1 | 2016 | 406 | 0.030 |
Why?
|
Chicago | 1 | 2019 | 1379 | 0.030 |
Why?
|
Cell Death | 1 | 2016 | 256 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2019 | 1805 | 0.030 |
Why?
|
Lung Diseases | 1 | 2017 | 263 | 0.030 |
Why?
|
Myofibroblasts | 1 | 2015 | 43 | 0.030 |
Why?
|
Multivariate Analysis | 1 | 2017 | 999 | 0.030 |
Why?
|
Anti-Infective Agents | 1 | 2015 | 89 | 0.030 |
Why?
|
Disease-Free Survival | 1 | 2017 | 1204 | 0.030 |
Why?
|
Liver Neoplasms | 1 | 2001 | 736 | 0.030 |
Why?
|
KATP Channels | 1 | 2014 | 19 | 0.030 |
Why?
|
Ultrasonography, Doppler | 1 | 2014 | 80 | 0.030 |
Why?
|
Adenosine Triphosphatases | 1 | 2015 | 153 | 0.030 |
Why?
|
Radiography, Abdominal | 1 | 2014 | 71 | 0.030 |
Why?
|
Membrane Potential, Mitochondrial | 1 | 2014 | 29 | 0.030 |
Why?
|
Pandemics | 1 | 2020 | 740 | 0.030 |
Why?
|
Carotid Body | 1 | 2017 | 234 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2018 | 1961 | 0.030 |
Why?
|
Enzyme Activation | 1 | 2015 | 692 | 0.030 |
Why?
|
Aortography | 1 | 2013 | 63 | 0.030 |
Why?
|
rho GTP-Binding Proteins | 1 | 2013 | 54 | 0.030 |
Why?
|
Fatty Acids | 1 | 2014 | 130 | 0.030 |
Why?
|
Endothelial Cells | 1 | 2016 | 428 | 0.030 |
Why?
|
Body Weight | 1 | 2014 | 459 | 0.030 |
Why?
|
Calgranulin B | 1 | 2013 | 16 | 0.030 |
Why?
|
Tetrazolium Salts | 1 | 2012 | 11 | 0.030 |
Why?
|
rhoA GTP-Binding Protein | 1 | 2013 | 83 | 0.030 |
Why?
|
Omalizumab | 1 | 2012 | 8 | 0.030 |
Why?
|
Hypotension | 1 | 2013 | 70 | 0.030 |
Why?
|
NFATC Transcription Factors | 1 | 2012 | 29 | 0.030 |
Why?
|
Leucine | 1 | 2012 | 67 | 0.030 |
Why?
|
Histone Demethylases | 1 | 2012 | 30 | 0.030 |
Why?
|
Acute Disease | 1 | 2014 | 826 | 0.030 |
Why?
|
Zinc | 1 | 2013 | 91 | 0.030 |
Why?
|
NAV1.5 Voltage-Gated Sodium Channel | 1 | 2012 | 31 | 0.030 |
Why?
|
Immunoglobulin E | 1 | 2012 | 144 | 0.030 |
Why?
|
Gene Knockout Techniques | 1 | 2012 | 77 | 0.030 |
Why?
|
Head and Neck Neoplasms | 1 | 2019 | 1052 | 0.030 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2017 | 663 | 0.030 |
Why?
|
Diet, High-Fat | 1 | 2013 | 114 | 0.030 |
Why?
|
Heart Diseases | 1 | 2014 | 290 | 0.030 |
Why?
|
Thiazoles | 1 | 2012 | 131 | 0.030 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2012 | 114 | 0.030 |
Why?
|
Eosinophils | 1 | 2012 | 194 | 0.030 |
Why?
|
Aorta, Thoracic | 1 | 2013 | 165 | 0.030 |
Why?
|
Quality of Life | 1 | 2020 | 1585 | 0.030 |
Why?
|
Fibrosis | 1 | 2012 | 203 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 376 | 0.030 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2012 | 273 | 0.030 |
Why?
|
Carrier Proteins | 1 | 2015 | 673 | 0.030 |
Why?
|
Stroke | 1 | 2020 | 965 | 0.030 |
Why?
|
Surveys and Questionnaires | 1 | 2019 | 2501 | 0.020 |
Why?
|
Myocardial Contraction | 1 | 2012 | 244 | 0.020 |
Why?
|
Retreatment | 1 | 2011 | 107 | 0.020 |
Why?
|
Body Mass Index | 1 | 2014 | 770 | 0.020 |
Why?
|
Cross-Sectional Studies | 1 | 2016 | 1621 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2013 | 1014 | 0.020 |
Why?
|
Cell Membrane | 1 | 2014 | 666 | 0.020 |
Why?
|
Up-Regulation | 1 | 2013 | 712 | 0.020 |
Why?
|
Connexins | 1 | 2012 | 200 | 0.020 |
Why?
|
Rats, Mutant Strains | 1 | 2010 | 23 | 0.020 |
Why?
|
SOXD Transcription Factors | 1 | 2010 | 1 | 0.020 |
Why?
|
Losartan | 1 | 2010 | 42 | 0.020 |
Why?
|
Biomimetics | 1 | 2010 | 29 | 0.020 |
Why?
|
Butadienes | 1 | 2010 | 33 | 0.020 |
Why?
|
Microarray Analysis | 1 | 2010 | 96 | 0.020 |
Why?
|
SOX9 Transcription Factor | 1 | 2010 | 23 | 0.020 |
Why?
|
Renin | 1 | 2010 | 79 | 0.020 |
Why?
|
NADPH Oxidases | 1 | 2010 | 81 | 0.020 |
Why?
|
Aggrecans | 1 | 2010 | 42 | 0.020 |
Why?
|
Enhancer Elements, Genetic | 1 | 2012 | 266 | 0.020 |
Why?
|
Chondrocytes | 1 | 2010 | 60 | 0.020 |
Why?
|
Heterochromatin | 1 | 2009 | 22 | 0.020 |
Why?
|
Hypertrophy | 1 | 2009 | 62 | 0.020 |
Why?
|
Vitamins | 1 | 2010 | 81 | 0.020 |
Why?
|
Diet | 1 | 2013 | 443 | 0.020 |
Why?
|
Nuclear Envelope | 1 | 2009 | 36 | 0.020 |
Why?
|
Chromatin | 1 | 2012 | 380 | 0.020 |
Why?
|
Mice, Mutant Strains | 1 | 2010 | 229 | 0.020 |
Why?
|
Forkhead Box Protein O3 | 1 | 2009 | 20 | 0.020 |
Why?
|
Stress Fibers | 1 | 2009 | 23 | 0.020 |
Why?
|
Nitriles | 1 | 2010 | 149 | 0.020 |
Why?
|
Hydrogen Peroxide | 1 | 2010 | 158 | 0.020 |
Why?
|
Catalase | 1 | 2009 | 48 | 0.020 |
Why?
|
In Situ Hybridization | 1 | 2010 | 307 | 0.020 |
Why?
|
Laminin | 1 | 2009 | 85 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2010 | 316 | 0.020 |
Why?
|
Binding Sites | 1 | 2012 | 1098 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2012 | 937 | 0.020 |
Why?
|
Gene Expression | 1 | 2013 | 1284 | 0.020 |
Why?
|
Adenoviridae | 1 | 2010 | 345 | 0.020 |
Why?
|
Cytoskeletal Proteins | 1 | 2009 | 223 | 0.020 |
Why?
|
DNA Primers | 1 | 2009 | 543 | 0.020 |
Why?
|
Membrane Proteins | 1 | 2015 | 1196 | 0.020 |
Why?
|
Blotting, Western | 1 | 2010 | 782 | 0.020 |
Why?
|
Interleukin-6 | 1 | 2009 | 256 | 0.020 |
Why?
|
Prostatic Neoplasms | 1 | 2019 | 1721 | 0.020 |
Why?
|
Antioxidants | 1 | 2009 | 223 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 879 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 2010 | 639 | 0.020 |
Why?
|
Indiana | 1 | 2006 | 12 | 0.020 |
Why?
|
Antihypertensive Agents | 1 | 2010 | 521 | 0.020 |
Why?
|
Etanercept | 1 | 2005 | 32 | 0.020 |
Why?
|
Base Sequence | 1 | 2009 | 2330 | 0.020 |
Why?
|
Skin Diseases | 1 | 2006 | 166 | 0.020 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2006 | 261 | 0.010 |
Why?
|
Surgical Instruments | 1 | 2004 | 57 | 0.010 |
Why?
|
Apoptosis | 1 | 2010 | 1683 | 0.010 |
Why?
|
Carcinoma, Renal Cell | 1 | 2006 | 426 | 0.010 |
Why?
|
Kidney Neoplasms | 1 | 2006 | 621 | 0.010 |
Why?
|